We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
The median survival after diagnosis of carcinomatousmeningitis was 77 days.
2
Approximately 50% of patients with carcinomatousmeningitis die from other causes, including systemic disease.
3
Therefore, large studies to assess the value of CSF tumor marker changes in carcinomatousmeningitis are warranted.
4
Given our findings, CSF tumor marker evaluation may provide a reliable means and surrogate end-points of monitoring response of carcinomatousmeningitis to treatment.
5
Conclusions: Given our findings, CSF tumor marker evaluation may provide a reliable means and surrogate end-points of monitoring response of carcinomatousmeningitis to treatment.
6
Carcinomatousmeningitis (CM) is an uncommon but devastating complication of malignancy.
7
Conclusions: Carcinomatousmeningitis from breast carcinoma is an aggressive metastatic complication with a poor prognosis.
8
Background: Carcinomatousmeningitis is a rare and often devastating complication in patients with breast cancer, and the treatment is controversial.